Nobutaka Ikeda, Yugo Yamashita, Takeshi Morimoto, Ryuki Chatani, Kazuhisa Kaneda, Yuji Nishimoto, Yohei Kobayashi, Satoshi Ikeda, Kitae Kim, Moriaki Inoko, et al. Incidence of Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism in the Era of Direct Oral Anticoagulants: From the COMMAND VTE Registry-2. Journal of the American Heart Association. 2024. e035997
Ryusuke Nishikawa, Yugo Yamashita, Takeshi Morimoto, Kazuhisa Kaneda, Ryuki Chatani, Yuji Nishimoto, Nobutaka Ikeda, Yohei Kobayashi, Satoshi Ikeda, Kitae Kim, et al. Selection of Home Treatment and Identification of Low-Risk Patients With Pulmonary Embolism Based on Simplified Pulmonary Embolism Severity Index Score in the Era of Direct Oral Anticoagulants. Journal of the American Heart Association. 2024. 13. 19. e034953
Shinya Fujiki, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Michihisa Umetsu, Yuji Nishimoto, Takuma Takada, Yoshito Ogihara, Tatsuya Nishikawa, Nobutaka Ikeda, et al. Impact of Anemia on Clinical Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis Receiving Edoxaban - Insights From the ONCO DVT Study. Circulation journal : official journal of the Japanese Circulation Society. 2024
Wei Xiong, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Michihisa Umetsu, Yuji Nishimoto, Takuma Takada, Yoshito Ogihara, Tatsuya Nishikawa, Nobutaka Ikeda, et al. Utility of the Modified Ottawa Score for Identification of More Preferable Candidates of Extended Anticoagulation therapy in Cancer-associated Isolated Distal Deep Vein Thrombosis: Insight from the ONCO DVT Study. Journal of thrombosis and haemostasis : JTH. 2024
Yoshito Ogihara, Norikazu Yamada, Daisuke Izumi, Yuichi Sato, Toru Sato, Hitoshi Nakaya, Tatsuya Mori, Satoshi Ota, Midori Makino, Toru Ogura, et al. Exploratory rivaroxaban trial for isolated calf deep vein thrombosis with a risk factor of thrombosis extension: an open-label, multicenter, randomized controlled trial. Research and Practice in Thrombosis and Haemostasis. 2024. 8. 5. 102515-102515
